Limited duration of complete remission on ruxolitinib in myeloid neoplasms with PCM1-JAK2 and BCR-JAK2 fusion genes.
Schwaab J, Knut M, Haferlach C, Metzgeroth G, Horny HP, Chase A, Tapper W, Score J, Waghorn K, Naumann N, Jawhar M, Fabarius A, Hofmann WK, Cross NC, Reiter A.
Schwaab J, et al. Among authors: naumann n.
Ann Hematol. 2015 Feb;94(2):233-8. doi: 10.1007/s00277-014-2221-y. Epub 2014 Sep 27.
Ann Hematol. 2015.
PMID: 25260694